GSK (GSK) shares fall as 2026 sales growth guidance sparks investor concerns
GSK plc shares are trading down 3.2% on the London Stock Exchange today, as investor concerns mounted over the company's guidance for slower sales growth in 2026. The pharmaceutical giant is currently trading at £2,075.00, down from yesterday's close of £2,144.00.
The decline follows GSK's projection of 3-5% sales growth for 2026, a notable moderation from the 7% growth achieved in 2025. This revised outlook is driven by an impending HIV drug patent expiry and a US deal with the Trump administration aimed at lowering drug prices. The company's recently released 2025 annual results reported 4% turnover growth to £32.6 billion and an 8% increase in core operating profit to £9.7 billion.
Despite the 2025 performance, GSK highlighted significant headwinds for 2026, including declining vaccine and general medicine sales, expected to be in the low single-digits to stable. Growth in specialty medicines is also forecast to moderate to low double-digits or stable. Consensus analyst targets, including a recent JPMorgan hike to 2,250p, underscore the pressure on the stock.
Why GSK's Slower Growth Forecast is Weighing on Shares
GSK plc develops, manufactures, and sells a wide range of pharmaceutical products, vaccines, and consumer healthcare items. Their business revolves around researching new treatments, producing established medicines, and distributing these to patients and healthcare providers globally. They generate revenue by selling these products, which address various health conditions from infectious diseases to chronic illnesses.
The primary driver behind today's share movement is GSK's updated sales growth forecast for 2026, which has fallen short of investor expectations. While the company reported a strong 7% sales growth for 2025, it now projects a more modest 3-5% growth for the upcoming year. This revised outlook stems from significant headwinds, including an impending patent expiry for a key HIV drug and a US deal with the Trump administration designed to lower drug prices, alongside expected moderation in vaccine and general medicine sales.
This recalibration of future growth expectations has led investors to reassess the company's valuation, resulting in GSK's shares trading down 3.2% today. The stock is currently trading at £2,075.00, a notable decline from yesterday's close of £2,144.00.
Think of it like a popular band that announces its next album will sell fewer copies than its last record, despite the previous one being a massive hit. Even with past success, the revised, lower expectation for future performance can disappoint fans and affect the band's perceived value in the industry.
GSK plc
GSK plc (GSK) operates as a diversified healthcare company, developing and marketing a broad portfolio of pharmaceutical products, vaccines, and consumer health goods across the UK, US, and international markets. Its operations are structured into four key segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The pharmaceutical division focuses on therapeutic areas including respiratory, HIV, oncology, and immunology, while its consumer health offerings span wellness, oral health, nutrition, and skin health categories, available in various formats such as tablets, creams, and dental care products. GSK engages in numerous collaborations with partners like 23andMe, Novartis, and Sanofi SA, alongside strategic partnerships with IDEAYA Biosciences and Vir Biotechnology. Formerly GlaxoSmithKline plc, the company rebranded in May 2022 and has roots dating back to 1715, with its headquarters located in Brentford, United Kingdom.